Linked Life Data

19883776

Source:http://linkedlifedata.com/resource/pubmed/id/19883776

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19883776rdf:typepubmed:Citationlld:pubmed
pubmed-article:19883776lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C0079744lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C0472699lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C0024312lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C1522577lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C1516048lld:lifeskim
pubmed-article:19883776lifeskim:mentionsumls-concept:C0205547lld:lifeskim
pubmed-article:19883776pubmed:issue3lld:pubmed
pubmed-article:19883776pubmed:dateCreated2010-2-15lld:pubmed
pubmed-article:19883776pubmed:abstractTextA specific predictor during routine follow-up to ascertain risk for postautologous peripheral blood hematopoietic stem cell transplantation (post-APHSCT) relapse in non-Hodgkin lymphoma (NHL) has not been identified. Thus, we studied if new-onset lymphopenia measured by the absolute lymphocyte count (ALC) was a marker of post-APHSCT NHL relapse. ALC was obtained at the time of confirmed relapse, and at last follow-up with no relapse. From 1993 until 2005, 269 patients treated with APHSCT for diffuse large B-cell lymphoma (DLBCL) were included in this study. Patients at last follow-up without relapse (N=137) had a higher ALC compared with those with low ALC at the time of confirmed relapsed (N=132) (median ALC x10(9)/L of 1.66 versus 0.71, P < .0001, respectively). ALC at follow-up was a strong predictor for relapse with an area under the curve (AUC)=0.86 (P < .0001). An ALC <1.0 x 10(9)/L at the time of confirmed relapse had a positive predictive value of 89% and a positive likelihood ratio of 8.4 to predict relapse post-APHSCT. Patients with an ALC > or =1.0 x 10(9)/L (N=147) had a cumulative incidence of relapse of 19% versus 92%, with an ALC <1.0 x 10(9)/L (N=122) (P < .0001). This study suggests that new-onset lymphopenia measured by ALC can be used as marker to assess risk of DLBCL relapse during routine follow-up for after APHSCT.lld:pubmed
pubmed-article:19883776pubmed:languageenglld:pubmed
pubmed-article:19883776pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19883776pubmed:citationSubsetIMlld:pubmed
pubmed-article:19883776pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19883776pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19883776pubmed:statusMEDLINElld:pubmed
pubmed-article:19883776pubmed:monthMarlld:pubmed
pubmed-article:19883776pubmed:issn1523-6536lld:pubmed
pubmed-article:19883776pubmed:authorpubmed-author:AnsellStephen...lld:pubmed
pubmed-article:19883776pubmed:authorpubmed-author:MarkovicSveto...lld:pubmed
pubmed-article:19883776pubmed:authorpubmed-author:PorrataLuis...lld:pubmed
pubmed-article:19883776pubmed:authorpubmed-author:InwardsDavid...lld:pubmed
pubmed-article:19883776pubmed:authorpubmed-author:MicallefIvana...lld:pubmed
pubmed-article:19883776pubmed:authorpubmed-author:HoganWilliam...lld:pubmed
pubmed-article:19883776pubmed:authorpubmed-author:JohnstonPatri...lld:pubmed
pubmed-article:19883776pubmed:copyrightInfoCopyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:19883776pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19883776pubmed:volume16lld:pubmed
pubmed-article:19883776pubmed:ownerNLMlld:pubmed
pubmed-article:19883776pubmed:authorsCompleteYlld:pubmed
pubmed-article:19883776pubmed:pagination376-83lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:meshHeadingpubmed-meshheading:19883776...lld:pubmed
pubmed-article:19883776pubmed:year2010lld:pubmed
pubmed-article:19883776pubmed:articleTitleNew-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.lld:pubmed
pubmed-article:19883776pubmed:affiliationDivision of Hematology/Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. porrata.luis@mayo.edulld:pubmed
pubmed-article:19883776pubmed:publicationTypeJournal Articlelld:pubmed